ES2912267T3 - Métodos de tratamiento de enfermedades asociadas a S. aureus - Google Patents
Métodos de tratamiento de enfermedades asociadas a S. aureus Download PDFInfo
- Publication number
- ES2912267T3 ES2912267T3 ES13853844T ES13853844T ES2912267T3 ES 2912267 T3 ES2912267 T3 ES 2912267T3 ES 13853844 T ES13853844 T ES 13853844T ES 13853844 T ES13853844 T ES 13853844T ES 2912267 T3 ES2912267 T3 ES 2912267T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- aureus
- amino acid
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723128P | 2012-11-06 | 2012-11-06 | |
| PCT/US2013/068385 WO2014074470A1 (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2912267T3 true ES2912267T3 (es) | 2022-05-25 |
Family
ID=50685101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13853844T Active ES2912267T3 (es) | 2012-11-06 | 2013-11-05 | Métodos de tratamiento de enfermedades asociadas a S. aureus |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9845348B2 (enExample) |
| EP (1) | EP2928490B1 (enExample) |
| JP (2) | JP6506172B2 (enExample) |
| KR (3) | KR20210083389A (enExample) |
| CN (2) | CN112316135A (enExample) |
| AU (2) | AU2013341421A1 (enExample) |
| BR (1) | BR112015010126B1 (enExample) |
| CA (1) | CA2890385C (enExample) |
| ES (1) | ES2912267T3 (enExample) |
| MX (1) | MX367082B (enExample) |
| RU (1) | RU2661406C2 (enExample) |
| SG (2) | SG10201703677VA (enExample) |
| WO (1) | WO2014074470A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012267732A1 (en) | 2011-06-10 | 2014-01-09 | Medimmune Limited | Anti-Pseudomonas Psl binding molecules and uses thereof |
| WO2013070615A1 (en) * | 2011-11-07 | 2013-05-16 | Medlmmune, Llc. | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
| EP2917360B1 (en) * | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| ES2912267T3 (es) * | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| WO2020076790A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
| MX2021004173A (es) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
| JP7682795B2 (ja) | 2019-03-13 | 2025-05-26 | メディミューン，エルエルシー | コロニー形成患者における黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症の低減 |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539979A (ja) * | 2006-06-12 | 2009-11-19 | ナビ バイオファーマシューティカルズ | ブドウ球菌感染症を治療および予防するための、α毒素の使用 |
| KR20100072228A (ko) * | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| EP2453881A2 (en) * | 2009-07-16 | 2012-05-23 | Georgia Health Sciences University Research Institute, Inc. | Porous-wall hollow glass microspheres as carriers for biomolecules |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| RS58190B2 (sr) | 2011-02-08 | 2021-08-31 | Medimmune Llc | Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene |
| AU2012214677B2 (en) * | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| EP2917360B1 (en) | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| ES2912267T3 (es) * | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
-
2013
- 2013-11-05 ES ES13853844T patent/ES2912267T3/es active Active
- 2013-11-05 JP JP2015540852A patent/JP6506172B2/ja active Active
- 2013-11-05 SG SG10201703677VA patent/SG10201703677VA/en unknown
- 2013-11-05 SG SG11201503231YA patent/SG11201503231YA/en unknown
- 2013-11-05 KR KR1020217020104A patent/KR20210083389A/ko not_active Ceased
- 2013-11-05 BR BR112015010126-7A patent/BR112015010126B1/pt active IP Right Grant
- 2013-11-05 WO PCT/US2013/068385 patent/WO2014074470A1/en not_active Ceased
- 2013-11-05 EP EP13853844.2A patent/EP2928490B1/en active Active
- 2013-11-05 KR KR1020157011460A patent/KR20150092738A/ko not_active Ceased
- 2013-11-05 CN CN202011217117.7A patent/CN112316135A/zh active Pending
- 2013-11-05 MX MX2015005481A patent/MX367082B/es active IP Right Grant
- 2013-11-05 KR KR1020207024078A patent/KR102272744B1/ko active Active
- 2013-11-05 CA CA2890385A patent/CA2890385C/en active Active
- 2013-11-05 AU AU2013341421A patent/AU2013341421A1/en not_active Abandoned
- 2013-11-05 RU RU2015121617A patent/RU2661406C2/ru active
- 2013-11-05 CN CN201380057604.3A patent/CN104780934A/zh active Pending
- 2013-11-05 US US14/440,749 patent/US9845348B2/en active Active
-
2017
- 2017-12-18 US US15/845,701 patent/US10457724B2/en active Active
-
2018
- 2018-09-28 AU AU2018236849A patent/AU2018236849B2/en active Active
-
2019
- 2019-03-28 JP JP2019063358A patent/JP6926138B2/ja active Active
- 2019-10-11 US US16/599,595 patent/US10759849B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10759849B2 (en) | Methods of treating S. aureus-associated diseases | |
| JP6694269B2 (ja) | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 | |
| US12570744B2 (en) | Bispecific PD-1 and TIGIT binding proteins and uses thereof | |
| BR112013020086B1 (pt) | Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina | |
| CA2866943A1 (en) | Treatment of multiple sclerosis with anti-cd19 antibody | |
| JP2022512647A (ja) | 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ | |
| US20240109961A1 (en) | Treatment of chronic prurigo | |
| HK1215173B (en) | Methods of treating s. aureus-associated diseases | |
| US20240392005A1 (en) | Pd-1/tigit binding proteins for cancer treatment | |
| TW202511292A (zh) | 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白 | |
| WO2025250726A1 (en) | Anti-kit antibody dosing and methods | |
| CN117120089A (zh) | 慢性痒疹的治疗 | |
| HK40025295A (en) | Antibodies to s. aureus surface determinants | |
| HK1215452B (en) | Antibodies to s. aureus surface determinants |